CYTOKINETICS INC

(c) In this Item 5(c) of this quarterly report on Form 10-Q, the terms “officers”, “rule 10b5-1 trading arrangements” and “non-Rule 10b5-1 trading arrangements” have the meanings ascribed to them in Item 408 of Regulation S-K.

The following directors and officers adopted into or terminated a Rule 10b5-1 trading arrangement during the third quarter of 2024:

•

John T. Henderson, Chairman of our Board of Directors – Dr. Henderson adopted a Rule 10b5-1 trading arrangement on September 11, 2024 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Henderson Plan”). The Henderson Plan provides for the exercise of stock options to acquire up to 31,872 shares of our common stock and the concurrent sale of all shares of common stock acquired upon such exercise at market prices, in each case, at pre-specified dates during the term of the plan. The Henderson Plan will terminate on the earlier of (x)May 20, 2025 and (y) the sale of all securities that are subject to the plan.

•

Fady Malik, Executive Vice President, Research and Development – Dr. Malik adopted a Rule 10b5-1 trading arrangement on September 16, 2024 that was intended to satisfy the affirmative defense provided for under Rule 10b5-1(c) (the “Malik Plan”). The Malik Plan provides for the exercise of stock options to acquire up to 49,000 shares of our common stock and the concurrent sale of all shares of common stock acquired upon such exercise at market prices, in each case at pre-specified dates during the term of the plan. The Malik Plan will terminate on the earlier of (x)December 19, 2025 and (y) the sale of all securities that are subject to the plan.

Certain of our officers have made elections to participate in, and are participating in, our employee stock purchase plan, which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements. In addition, certain of our directors have made elections to participate in, and are participating in, our director equity in lieu of cash retainer option program (as described in the “Director Compensation” section of our Proxy Statement for our 2024 Annual Meeting), which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1 under the Exchange Act or may constitute non-Rule 10b5–1 trading arrangements.